All In Biotech

Drug Trial Radar · NCT07711002

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

A Randomized, Double-Blind, Placebo-Controlled, 2-Cohort, Phase III Study of Saruparib Combined With Physician's Choice of Androgen Receptor Pathway Inhibitor in Patients With Metastatic Hormone-Sensitive Prostate Cancer, Previously Treated With Docetaxel or PSMA-directed 177Lutetium-Containing Therapy Without Disease Progression, and With Prostate-Specific Antigen ≥ 0.2 ng/mL: EvoPAR-Prostate05

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,330 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,330

Planned (sponsor's estimate)

Start

Sep 15, 2026

Primary completion

May 30, 2031

Study completion May 27, 2033

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA ≥ 0.2 ng/mL.

Conditions

  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Interventions

  • SaruparibDrug

    Arm 1: Saruparib (AZD5305) + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone)

  • PlaceboOther

    Arm 2: Placebo + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone)

  • EnzalutamideDrug

    Arm 1: Saruparib (AZD5305) + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone) Arm 2: Placebo + Physician's Choice ARPI

  • DarolutamideDrug

    Arm 1: Saruparib (AZD5305) + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone) Arm 2: Placebo + Physician's Choice ARPI

  • AbirateroneDrug

    Arm 1: Saruparib (AZD5305) + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone) Arm 2: Placebo + Physician's Choice ARPI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic progression-free survival (rPFS)Time frame: Up to approximately 56 months

Locations

210 sites in 21 countries. Site status is shown where the registry gives one.

  • Research Site

    Hot Springs, Arkansas · Not yet recruiting

  • Research Site

    Springdale, Arkansas · Recruiting

  • Research Site

    Beverly Hills, California · Not yet recruiting

  • Research Site

    Los Alamitos, California · Not yet recruiting

  • Research Site

    Los Angeles, California · Not yet recruiting

  • Research Site

    San Diego, California · Withdrawn

  • Research Site

    Margate, Florida · Recruiting

  • Research Site

    Miami, Florida · Recruiting

  • Research Site

    Orlando, Florida · Not yet recruiting

  • Research Site

    Honolulu, Hawaii · Not yet recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Elk Grove Village, Illinois · Not yet recruiting

  • Research Site

    Hinsdale, Illinois · Not yet recruiting

  • Research Site

    Ames, Iowa · Not yet recruiting

  • Research Site

    Baltimore, Maryland · Not yet recruiting

  • Research Site

    Baltimore, Maryland · Not yet recruiting

  • Research Site

    Towson, Maryland · Not yet recruiting

  • Research Site

    Detroit, Michigan · Not yet recruiting

  • Research Site

    Grand Rapids, Michigan · Not yet recruiting

  • Research Site

    Marshall, Minnesota · Not yet recruiting

  • Research Site

    Camden, New Jersey · Not yet recruiting

  • Research Site

    Albuquerque, New Mexico · Not yet recruiting

  • Research Site

    Shirley, New York · Not yet recruiting

  • Research Site

    Canton, Ohio · Not yet recruiting

  • Research Site

    Cincinnati, Ohio · Not yet recruiting

  • Research Site

    Portland, Oregon · Not yet recruiting

  • Research Site

    Portland, Oregon · Not yet recruiting

  • Research Site

    Greenville, South Carolina · Not yet recruiting

  • Research Site

    Aberdeen, South Dakota · Not yet recruiting

  • Research Site

    Mitchell, South Dakota · Not yet recruiting

  • Research Site

    Pierre, South Dakota · Not yet recruiting

  • Research Site

    Sioux Falls, South Dakota · Not yet recruiting

  • Research Site

    Yankton, South Dakota · Not yet recruiting

  • Research Site

    Nashville, Tennessee · Not yet recruiting

  • Research Site

    Austin, Texas · Not yet recruiting

  • Research Site

    Dallas, Texas · Not yet recruiting

  • Research Site

    Fort Worth, Texas · Not yet recruiting

  • Research Site

    Longview, Texas · Not yet recruiting

  • Research Site

    Wichita Falls, Texas · Not yet recruiting

Showing 40 of 210 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.